...We Welcome You To The Resverlogix HUB withIn The AGORACOM COMMUNITY!

Free
Message: Re: Resverlogix Announces Publication on Apabetalone in Clinical Epigenetics

"With my revisions above, this BETonMACE total patient years would be 4960 to 5432 total BETonMACE patient years. "

Assuming 263 total events (250 at mid-April plus a guess that 13 happened since) yields a blended rate of 5.3 to 4.8 events per 100 patient years, respectively.

We don't know the placebo event rate. However, the placebo rate could be as low as 6.25 per 100 patient years and the aggregate event rates would still differ by at least 30%.

The endpoint is actually time to MACE, not comparing the total events in each group as I did here, but you get the idea -- if the above numbers are accurate it's looking good!

Share
New Message
Please login to post a reply